Mon, Sep 15, 2014, 12:40 AM EDT - U.S. Markets open in 8 hrs 50 mins


% | $
Quotes you view appear here for quick access.

Infinity Pharmaceuticals, Inc. (INFI) Message Board

  • getintoh20 getintoh20 Jul 5, 2013 8:45 AM Flag

    Goldman Sachs today slashes pt from $40 to $20 Code word for SELL

    Goldman Sachs today maintained a Neutral rating on Infinity Pharmaceutical (NASDAQ: INFI) and cuts its price target to $20.00 (from $40.00). Analyst Navdeep Singh noted increased competitive pressures.

    "We are lowering our 12-month price target for INFI to $20 (from $40) due to (1) increased competitive pressure from Gilead's (Nasdaq: GILD) idelalisib, (2) uncertainty on IPI-145's (oral therapy for blood cancers) safety profile, and (3) lack of visibility on commercial positioning. We now project IPI-145 peak sales of $1bn (from $2.8bn) and assign no success (from a 20% probability of success) to retaspimycin (HSP-90 inhibitor for lung cancer) due to mixed competitor data at ASCO," said Singh.

    For an analyst ratings summary and ratings history on Infinity Pharmaceutical (NASDAQ: INFI) click here. For more ratings news on Infinity Pharmaceutical click here.

    Like i said going under $11. Short at well....Another great day for us shorts....

    SortNewest  |  Oldest  |  Most Replied Expand all replies
14.86-0.67(-4.31%)Sep 12 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
21Vianet Group, Inc.
NasdaqGSFri, Sep 12, 2014 4:00 PM EDT
Darden Restaurants, Inc.
NYSEFri, Sep 12, 2014 4:03 PM EDT